NO20054312L - HIV-replikasjonsinhiberende pyrimidiner og triaziner - Google Patents

HIV-replikasjonsinhiberende pyrimidiner og triaziner

Info

Publication number
NO20054312L
NO20054312L NO20054312A NO20054312A NO20054312L NO 20054312 L NO20054312 L NO 20054312L NO 20054312 A NO20054312 A NO 20054312A NO 20054312 A NO20054312 A NO 20054312A NO 20054312 L NO20054312 L NO 20054312L
Authority
NO
Norway
Prior art keywords
triazines
hiv replication
replication inhibitory
pyrimidines
inhibitory pyrimidines
Prior art date
Application number
NO20054312A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054312D0 (no
Inventor
Jan Heeres
Kurt Hertogs
Marc Rene De Jonge
Lucien Maria Henricus Koymans
Eva Bettens
Jerome Emile George Guillemont
Elisabeth Therese Jea Pasquier
Paulus Joannes Lewi
Frederik Frans Desire Daeyaert
Hendrik Maarten Vinkers
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20054312D0 publication Critical patent/NO20054312D0/no
Publication of NO20054312L publication Critical patent/NO20054312L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20054312A 2003-02-20 2005-09-19 HIV-replikasjonsinhiberende pyrimidiner og triaziner NO20054312L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
PCT/EP2004/050177 WO2004074262A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (2)

Publication Number Publication Date
NO20054312D0 NO20054312D0 (no) 2005-09-19
NO20054312L true NO20054312L (no) 2005-11-16

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20054311A NO20054311L (no) 2003-02-20 2005-09-19 HIV-repliksjonsinhiberende pyrimidiner og triaziner
NO20054312A NO20054312L (no) 2003-02-20 2005-09-19 HIV-replikasjonsinhiberende pyrimidiner og triaziner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20054311A NO20054311L (no) 2003-02-20 2005-09-19 HIV-repliksjonsinhiberende pyrimidiner og triaziner

Country Status (27)

Country Link
US (2) US7585870B2 (pt)
EP (2) EP1603887B1 (pt)
JP (2) JP4586014B2 (pt)
KR (2) KR20050094896A (pt)
CN (2) CN1751031B (pt)
AP (1) AP2005003373A0 (pt)
AR (2) AR044500A1 (pt)
AT (2) ATE506353T1 (pt)
AU (2) AU2004213187B2 (pt)
BR (2) BRPI0407741B8 (pt)
CA (2) CA2516699C (pt)
CL (2) CL2004000303A1 (pt)
CY (1) CY1106788T1 (pt)
DE (2) DE602004006383T2 (pt)
DK (1) DK1597238T3 (pt)
EA (2) EA011256B1 (pt)
ES (1) ES2287734T3 (pt)
HR (2) HRP20050821A2 (pt)
IL (2) IL169596A (pt)
MX (2) MXPA05008866A (pt)
MY (1) MY138308A (pt)
NO (2) NO20054311L (pt)
NZ (2) NZ541601A (pt)
PL (2) PL227295B1 (pt)
PT (1) PT1597238E (pt)
TW (2) TW200510339A (pt)
WO (2) WO2004074262A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE60330466D1 (de) 2002-07-29 2010-01-21 Rigel Pharmaceuticals Inc VERFAHREN ZUR BEHANDLUNG ODER PRuVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
NZ545270A (en) 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
ES2380550T3 (es) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Jak 경로의 억제를 위한 조성물 및 방법
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR20090094073A (ko) * 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Hiv를 억제하는 6-치환된 피리미딘
CN106045965A (zh) * 2006-12-29 2016-10-26 爱尔兰詹森科学公司 抑制hiv的5,6‑取代的嘧啶类化合物
EP2300013B1 (en) 2008-05-21 2017-09-06 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
NZ591366A (en) 2008-09-11 2012-05-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
KR101295937B1 (ko) 2009-03-11 2013-08-14 화이자 인코포레이티드 글루코카이네이즈 억제제로서 사용되는 벤조푸라닐 유도체
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP6740452B2 (ja) 2016-07-26 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
EP3966207B1 (en) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
JP2022531932A (ja) 2019-05-10 2022-07-12 デシフェラ・ファーマシューティカルズ,エルエルシー ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法
MX2021015628A (es) 2019-06-17 2022-04-18 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
EP0862463A1 (en) 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
AU751573C (en) * 1998-03-27 2003-10-09 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
KR100658489B1 (ko) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Hiv 복제를 억제하는 피리미딘
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
PT1225874E (pt) * 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv Composicoes antivirais.
AU770600B2 (en) * 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
WO2002036578A2 (en) 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN102151273B (zh) * 2002-02-05 2015-11-25 安斯泰来制药有限公司 2,4,6-三氨基-1,3,5-三嗪衍生物
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US7449456B2 (en) * 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
DE60330466D1 (de) * 2002-07-29 2010-01-21 Rigel Pharmaceuticals Inc VERFAHREN ZUR BEHANDLUNG ODER PRuVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

Also Published As

Publication number Publication date
JP2006518357A (ja) 2006-08-10
CA2516589A1 (en) 2004-09-02
EA200501327A1 (ru) 2006-02-24
CY1106788T1 (el) 2012-05-23
CN1751031A (zh) 2006-03-22
DE602004032321D1 (de) 2011-06-01
EA200501326A1 (ru) 2006-02-24
EP1597238A1 (en) 2005-11-23
HRP20050821A2 (en) 2006-11-30
AR044500A1 (es) 2005-09-14
DE602004006383T2 (de) 2008-01-10
IL169647A (en) 2013-05-30
US20060142571A1 (en) 2006-06-29
TW200510339A (en) 2005-03-16
AU2004213187A1 (en) 2004-09-02
CA2516589C (en) 2012-04-17
AP2005003373A0 (en) 2005-09-30
AU2004213186B2 (en) 2009-10-01
CN100572364C (zh) 2009-12-23
EA011256B1 (ru) 2009-02-27
BRPI0407741B8 (pt) 2021-05-25
CA2516699C (en) 2011-07-12
US20060194804A1 (en) 2006-08-31
NO20054312D0 (no) 2005-09-19
EP1603887A1 (en) 2005-12-14
PL378136A1 (pl) 2006-03-06
JP4586013B2 (ja) 2010-11-24
PT1597238E (pt) 2007-08-08
AU2004213186A1 (en) 2004-09-02
CN1751030A (zh) 2006-03-22
NO20054311L (no) 2005-10-27
MXPA05008867A (es) 2005-10-05
DK1597238T3 (da) 2007-09-10
MXPA05008866A (es) 2005-10-05
NO20054311D0 (no) 2005-09-19
WO2004074262A1 (en) 2004-09-02
ES2287734T3 (es) 2007-12-16
PL226954B1 (pl) 2017-10-31
EP1603887B1 (en) 2011-04-20
CL2004000306A1 (es) 2005-04-08
KR20050094896A (ko) 2005-09-28
WO2004074261A1 (en) 2004-09-02
NZ541601A (en) 2007-09-28
ATE506353T1 (de) 2011-05-15
ATE361915T1 (de) 2007-06-15
CA2516699A1 (en) 2004-09-02
CL2004000303A1 (es) 2005-04-08
IL169596A (en) 2017-02-28
HRP20050820A2 (en) 2006-11-30
EP1597238B1 (en) 2007-05-09
KR20050099994A (ko) 2005-10-17
BRPI0407741A (pt) 2006-02-14
MY138308A (en) 2009-05-29
US7585870B2 (en) 2009-09-08
JP4586014B2 (ja) 2010-11-24
EA010423B1 (ru) 2008-08-29
PL227295B1 (pl) 2017-11-30
BRPI0407741B1 (pt) 2018-05-29
AR044499A1 (es) 2005-09-14
NZ542428A (en) 2007-11-30
JP2006518356A (ja) 2006-08-10
AU2004213187B2 (en) 2009-11-05
IL169596A0 (en) 2007-07-04
DE602004006383D1 (de) 2007-06-21
IL169647A0 (en) 2007-07-04
BRPI0407732A (pt) 2006-02-14
TW200500346A (en) 2005-01-01
CN1751031B (zh) 2010-07-21
US7442705B2 (en) 2008-10-28
PL378064A1 (pl) 2006-02-20

Similar Documents

Publication Publication Date Title
NO20054312L (no) HIV-replikasjonsinhiberende pyrimidiner og triaziner
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20062726L (no) Nye pyridazin-3(2H)-on derivater
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
DK1427708T3 (da) Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
NO20081844L (no) Terapeutiske forbindelser
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20090628L (no) Pyridizinon derivativater
NO20052739L (no) CCR5-antagonister som medikamenter
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
NO20071593L (no) Pyrimidinderivater
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
NO20064062L (no) Prodroger av piperazin og substituerte piperidin antivirale midler
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20066055L (no) Pyridinderivater
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
PL378107A1 (pl) 1,2,4-triazyny hamujące HIV
NO20085087L (no) Nye heterocykliske forbindelser
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application